Good link, thanks for the heads up when ER announces these kinds of numbers will pop big.
Sentiment: Strong Buy
Great DD Read on EXEL:
Biotech Stock ( EXEL ) Could Soon Double
First, Exelixis just reported fantastic top-line data from its late-stage METEOR study involving Cometriq as a treatment for advanced renal cell carcinoma. The primary endpoint of the study is a statistically significant improvement in median progression-free survival over Afinitor, and the results demonstrated a 42% reduction in the risk of disease progression or death. In previous studies (medullary thyroid cancer and the COMET-1 study), Cometriq also delivered a statistically significant improvement in PFS.
Secondly, the combo therapy of cobimetinib, discovered by Exelixis, and Roche 's Zelboraf, for BRAF V600 mutation-positive metastatic melanoma is coming up. Both the top-line data and updated data release at the American Society of Clinical Oncology's annual meeting showed a definitive statistical improvement in terms of PFS and response rate for the combo therapy compared to just Zelboraf alone.
Lastly, we should be hearing news from Roche, on a phase 1 study involving the combination of cobimetinibwith a Roche anti-PD-L1 therapy. Cancer immunotherapies are arguably the hottest topic of discussion among investors, and if cobimetinib can latch on as a combo therapy, Exelixis could see substantial revenue.
MD Anderson & ZIOP Immuno & Five CART-s, Near Term Catalysts
Biogen Enters Oversold Territory (BIIB)
By BNK Invest, July 24, 2015, 12:11:18 PM EDT
Do the DD daviberzerkowitz - Aricept and RVT-101 trials together have never failed. Kills me how folks come on and don't even know whats going on.